IBI362 Clinical Trials
5 recruitingDrug
Phase 33Phase 22
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Innovent Biologics (Suzhou) Co. Ltd.180 enrolled1 locationNCT07255209
Recruiting
Phase 2
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Innovent Biologics (Suzhou) Co. Ltd.165 enrolled1 locationNCT06937749
Recruiting
Phase 2
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Obesity
Innovent Biologics (Suzhou) Co. Ltd.141 enrolled1 locationNCT06862908
Recruiting
Phase 3
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
ObesitySleep ApneaObstructive
Innovent Biologics (Suzhou) Co. Ltd.260 enrolled1 locationNCT06931028
Recruiting
Phase 3
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
OverweightMetabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled1 locationNCT06884293